Stock comparison
LeMaitre Vascular
Zimmer Biomet Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
ZBH
Zimmer Biomet Holdings
Market cap
$16.54B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | ZBH | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 60D | LMAT |
| Benjamin Graham | 89A | 57C | LMAT |
| Philip Fisher | 81C | 55C | LMAT |
| Peter Lynch | 67B | 44D | LMAT |
| Joel Greenblatt | 56D | 32F | LMAT |
| Charlie Munger | 68D | 50D | LMAT |
| Terry Smith | 69D | 54D | LMAT |
Side-by-side metrics
| Metric | LMAT | ZBH |
|---|---|---|
| Market cap | $2.23B | $16.54B |
| P/E (TTM) | 37.1x | 21.4x |
| EV/EBIT | 36.6x | 17.1x |
| ROIC (TTM) | 9.43% | 4.98% |
| Gross margin | 72.39% | 70.03% |
| Net margin | 24.35% | 9.05% |
| Revenue CAGR 5y | 12.75% | 4.79% |
| EPS CAGR 5y | 19.04% | 16.54% |
| Debt / Equity | 0.5x | 0.5x |
| Dividend yield | 0.84% | 1.15% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Net margin24.35%vs 9.05%+63%
- Revenue CAGR 5y12.75%vs 4.79%+62%
- ROIC (TTM)9.43%vs 4.98%+47%
- EPS CAGR 5y19.04%vs 16.54%+13%
ZBH leads on
- Market cap$16.54Bvs $2.23B+86%
- EV/EBIT17.1xvs 36.6x+53%
- P/E (TTM)21.4xvs 37.1x+42%
- Dividend yield1.15%vs 0.84%+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.